Optimization of conditions for the production of small extracellular vesicles from human umbilical cord-derived mesenchymal stem cells

Home/2025, Vol. 13, No. 1/Optimization of conditions for the production of small extracellular vesicles from human umbilical cord-derived mesenchymal stem cells

Cell and Organ Transplantology. 2025; 13(1):32-44 (e2025131175).
DOI: 10.22494/cot.v13i1.175

Optimization of conditions for the production of small extracellular vesicles from human umbilical cord-derived mesenchymal stem cells

Gordiienko I.1,2, Shamshur M.1,3, Novikova S.3, Zlatskiy I.3, Zlatska A.1,3

  • 1Biotechnology Laboratory, Medical Company “Good Cells”, Kyiv, Ukraine
  • 2R. E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy of Sciences of Ukraine, Kyiv, Ukraine
  • 3Institute of Genetic and Regenerative Medicine, M. D. Strazhesko National Scientific Center of Cardiology, Clinical and Regenerative Medicine, National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine

Abstract

Extracellular vesicles (EVs), derived from mesenchymal stem cells (MSCs), play crucial roles in the physiological functions of MSCs and their therapeutic effects. Compared with cellular products, the composition of EVs, their biological properties, mechanisms of action, and superior stability make them attractive candidates for regenerative medicine, heralding a new era in cell therapy.
Aim – to identify optimal conditions for obtaining small EVs from cultured human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) based on quantitative indicators of EVs yield and the morpho-functional characteristics of MSC cultures depending on cultivation conditions.
Materials and methods. The MSCs were isolated from the human umbilical cord through enzymatic digestion. The process of optimizing the cultivation medium was conducted as follows. The first ways – culture medium was replaced with fresh medium and maintained for the subsequent 24 hours. The second ways – culture continued in the unaltered medium. Then they were changed to two media: Hank’s solution and MEM alpha medium, both without devoid of xenogeneic serum and exogenous growth factors. Cultivation and extracellular vesicles production from hUC-MSCs under serum-free conditions were carried out for 24, 48, and 72 hours. All vesicles were examined to confirm their specific size distribution, determined by nanoparticle tracking analysis (NTA), and the presence of CD63 and CD81 markers, as assessed by ELISA.
Results. Replacing the growth medium in the hUC-MSC culture 24 hours before switching to serum-free medium led to a significantly higher yield of extracellular vesicles. Upon transitioning the culture to serum-free medium, we identified a dependency on both the composition of the serum-free medium and the duration of MSC cultivation in these conditions. The highest yield of extracellular vesicles was observed after 48 and 72 hours of cultivation, with no significant difference observed between the serum-free medium compositions. We attribute this result to the adaptation period of the culture during the first 24 hours of serum-free cultivation. Given that no significant difference in extracellular vesicle yield was found between 48 and 72 hours, we propose 48 hours as the optimal cultivation time.
Conclusion. The findings of this study indicate that the optimal conditions for the cultivation of umbilical cord mesenchymal stem cells for the production of small extracellular vesicles in serum-free medium are as follows: culturing hUC-MSCs in complete growth medium with regular medium exchanges every 2-3 days until the culture achieves 70 % confluence; replacing the growth medium 24 hours prior to transitioning to serum-free medium; cultivating the hUC-MSC culture for 48 hours in Hank’s solution or MEM, without the addition of xenogeneic serum.

Key words: mesenchymal stem cells; extracellular vesicles; exosomes; serum-free medium

 


Full text PDF

1. Culme-Seymour EJ, Davie NL, Brindley DA, Edwards-Parton S, Mason C. A decade of cell therapy clinical trials (2000-2010). Regen Med. 2012 Jul;7(4):455-62.
https://doi.org/10.2217/rme.12.45
PMid:22817619
2. Mason C, Brindley DA, Culme-Seymour EJ, Davie NL. Cell therapy industry: billion dollar global business with unlimited potential. Regen Med. 2011 May;6(3):265-72.
https://doi.org/10.2217/rme.11.28
PMid:21548728
3. Brindley DA, Davie NL, Sahlman WA, Bonfiglio GA, Culme-Seymour EJ, Reeve BC, Mason C. Promising growth and investment in the cell therapy industry during the first quarter of 2012. Cell Stem Cell. 2012 May 4;10(5):492-6.
https://doi.org/10.1016/j.stem.2012.04.018
PMid:22560072
4. da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006 Jun 1;119(Pt 11):2204-13.
https://doi.org/10.1242/jcs.02932
PMid:16684817
5. Tang YL, Zhao Q, Zhang YC, Cheng L, Liu M, Shi J, Yang YZ, Pan C, Ge J, Phillips MI. Autologous mesenchymal stem cell transplantation induce VEGF and neovascularization in ischemic myocardium. Regul Pept. 2004 Jan 15;117(1):3-10.
https://doi.org/10.1016/j.regpep.2003.09.005
PMid:14687695
6. Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation. 2002 Jan 1;105(1):93-8.
https://doi.org/10.1161/hc0102.101442
PMid:11772882
7. Maitra B, Szekely E, Gjini K, Laughlin MJ, Dennis J, Haynesworth SE, Koç ON. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 2004 Mar;33(6):597-604.
https://doi.org/10.1038/sj.bmt.1704400
PMid:14716336
8. Honma T, Honmou O, Iihoshi S, Harada K, Houkin K, Hamada H, Kocsis JD. Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Exp Neurol. 2006 May;199(1):56-66.
https://doi.org/10.1016/j.expneurol.2005.05.004
PMid:15967439 PMCid:PMC2605388
9. Parekkadan B, Tilles AW, Yarmush ML. Bone marrow-derived mesenchymal stem cells ameliorate autoimmune enteropathy independently of regulatory T cells. Stem Cells. 2008 Jul;26(7):1913-9.
https://doi.org/10.1634/stemcells.2007-0790
PMid:18420833
10. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells. 2007 Oct;25(10):2648-59.
https://doi.org/10.1634/stemcells.2007-0226
PMid:17615264
11. Shumakov VI, Onishchenko NA, Rasulov MF, Krasheninnikov ME, Zaidenov VA. Mesenchymal bone marrow stem cells more effectively stimulate regeneration of deep burn wounds than embryonic fibroblasts. Bull Exp Biol Med. 2003 Aug;136(2):192-5.
https://doi.org/10.1023/A:1026387411627
PMid:14631508
12. McFarlin K, Gao X, Liu YB, Dulchavsky DS, Kwon D, Arbab AS, Bansal M, Li Y, Chopp M, Dulchavsky SA, Gautam SC. Bone marrow-derived mesenchymal stromal cells accelerate wound healing in the rat. Wound Repair Regen. 2006 Jul-Aug;14(4):471-8.
https://doi.org/10.1111/j.1743-6109.2006.00153.x
PMid:16939576
13. Fu X, Li H. Mesenchymal stem cells and skin wound repair and regeneration: possibilities and questions. Cell Tissue Res. 2009 Feb;335(2):317-21.
https://doi.org/10.1007/s00441-008-0724-3
PMid:19034523
14. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell. 2008 Feb 7;2(2):141-50.
https://doi.org/10.1016/j.stem.2007.11.014
PMid:18371435
15. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V, Uccelli A. Human mesenchymal stem cells modulate B-cell functions. Blood. 2006 Jan 1;107(1):367-72.
https://doi.org/10.1182/blood-2005-07-2657
PMid:16141348
16. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood. 2006 Feb 15;107(4):1484-90. doi: 10.1182/blood-2005-07-2775. Epub 2005 Oct 20. PMID: 16239427.
https://doi.org/10.1182/blood-2005-07-2775
PMid:16239427
17. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005 Feb 15;105(4):1815-22.
https://doi.org/10.1182/blood-2004-04-1559
PMid:15494428
18. Nasef A, Ashammakhi N, Fouillard L. Immunomodulatory effect of mesenchymal stromal cells: possible mechanisms. Regen Med. 2008 Jul;3(4):531-46.
https://doi.org/10.2217/17460751.3.4.531
PMid:18588475
19. Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Hassan M, Uzunel M, Ringdén O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004 May 1;363(9419):1439-41.
https://doi.org/10.1016/S0140-6736(04)16104-7
PMid:15121408
20. Parekkadan B, Milwid JM. Mesenchymal stem cells as therapeutics. Annu Rev Biomed Eng. 2010 Aug 15;12:87-117.
https://doi.org/10.1146/annurev-bioeng-070909-105309
PMid:20415588 PMCid:PMC3759519
21. Panda B, Sharma Y, Gupta S, Mohanty S. Mesenchymal Stem Cell-Derived Exosomes as an Emerging Paradigm for Regenerative Therapy and Nano-Medicine: A Comprehensive Review. Life (Basel). 2021 Aug 3;11(8):784.
https://doi.org/10.3390/life11080784
PMid:34440528 PMCid:PMC8399916
22. Almeria C, Kreß S, Weber V, Egger D, Kasper C. Heterogeneity of mesenchymal stem cell-derived extracellular vesicles is highly impacted by the tissue/cell source and culture conditions. Cell Biosci. 2022 May 2;12(1):51.
https://doi.org/10.1186/s13578-022-00786-7
PMid:35501833 PMCid:PMC9063275
23. Gordiienko I, Shamshur M, Novikova S, Zlatskiy I, Zlatska A. Regenerative potential and clinical application of mesenchymal stem cell-derived exosomes (review). Cell Organ Transpl. 2023; 11(2):66-80.
https://doi.org/10.22494/cot.v11i2.152
24. Yao T., Asayama Y. Animal-cell culture media: History, characteristics, and current issues Reprod Med Biol. 2017. vol. 16. no 2. Р. 99-117.
https://doi.org/10.1002/rmb2.12024
PMid:29259457 PMCid:PMC5661806
25. Czapla J, Matuszczak S, Kulik K, Wiśniewska E, Pilny E, Jarosz-Biej M, Smolarczyk R, Sirek T, Zembala MO, Zembala M, Szala S, Cichoń T. The effect of culture media on large-scale expansion and characteristic of adipose tissue-derived mesenchymal stromal cells. Stem Cell Res Ther. 2019 Aug 5;10(1):235.
https://doi.org/10.1186/s13287-019-1331-9
PMid:31383013 PMCid:PMC6683465
26. Rojewski MT, Fekete N, Baila S, Nguyen K, Fürst D, Antwiler D, Dausend J, Kreja L, Ignatius A, Sensebé L, Schrezenmeier H. GMP-compliant isolation and expansion of bone marrow-derived MSCs in the closed, automated device quantum cell expansion system. Cell Transplant. 2013;22(11):1981-2000.
https://doi.org/10.3727/096368912X657990
PMid:23107560
27. Eisenblatter T., Psathaki K., Nitz T., Galla H., Wegener J. Cell culture media: selection and standardization. In: Lehr C.M., ed. Cell Culture Models of Biological Barriers. In-Vitro Test Systems for Drug Absorption and Delivery. London: Taylor & Francis, 2002. Р. 20-40.
https://doi.org/10.1201/9780203219935.ch2
28. Van der Valk J., Brunner D., Smet K. De, Fex Svenningsen Е., Honegger P., Knudsen L.E., Lindl T., Noraberg J., Price A., Scarino M.L., Gstraunthaler G. Optimization of chemically defined cell culture media – Replacing fetal bovine serum in mammalian in vitro methods. Toxicology in Vitro. 2010. vol. 24. Р. 1053-1063.
https://doi.org/10.1016/j.tiv.2010.03.016
PMid:20362047
29. Meenakshi A. Cell culture media: a review. Mater Methods. 2013. vol. 3. Р. 175-203.
https://doi.org/10.13070/mm.en.3.175
30. Van der Valk J., Bieback K., Buta C., Cochrane B., Dirks W.G., Fu J., Hickman J.J., Hohensee C., Kolar R., Liebsch M., Pistollato F., Schulz M., Thieme D., Weber T., Wiest J., Winkler S., Gstraunthaler G. Fetal bovine serum (FBS): Past – Present – Future. Altex. 2018. vol. 35. no. 1. Р. 99-118.
https://doi.org/10.14573/altex.1705101
PMid:28800376
31. Zhang S., Liu Z., Su G., Wu H. Comparative analysis of KnockOutTM serum with fetal bovine serum for the in vitro longterm culture of human limbal epithelial cells. J. Ophthalmol. 2016. vol. 2016. 10 p.
https://doi.org/10.1155/2016/7304812
PMid:27446607 PMCid:PMC4944074
32. Butler M. Serum and protein free media. In: Al-Rubeai M. Animal cell culture. Switzerland: Springer International Publishing, 2015. Р. 223-236.
https://doi.org/10.1007/978-3-319-10320-4_8
33. Cimino M., Gonçalves R.M., Barrias C.C., Martins M.C.L. Xeno-free strategies for safe human mesenchymal stem/stromal cell expansion: Supplements and coatings. Stem Cells International, 2017. vol. 2017. Р. 56-68.
https://doi.org/10.1155/2017/6597815
PMid:29158740 PMCid:PMC5660800
34. Portner R. Characteristics of mammalian cells and requirements for cultivation. In: Eibl R., Eibl D., Portner R., Catapano G., Czermak P. Cell and tissue reaction engineering. – Verlag, Berlin, Heidelberg: Springer, 2009. Р. 13-53.
https://doi.org/10.1007/978-3-540-68182-3_2
35. Rodríguez-Hernández C.O., Torres-García S.E., Olvera-Sandoval C., Ramírez-Castillo F.Y., Muro A.L., Avelar-Gonzalez F.J., Guerrero-Barrera A.L. Cell culture: history, development and prospects. Int. J. Curr. Res. Aca. Rev. 2014. vol. 2. no. 12. Р. 188-200.
36. Oyeleye O.O., Ogundeji S.T., Ola S.I., Omitogun O.G. Basics of animal cell culture: Foundation for modern science. Biotechnol. Mol. Biol. Rev.. 2016. vol. 11. no. 2. Р. 6-16.
https://doi.org/10.5897/BMBR2016.0261
37. Bui HTH, Nguyen LT, Than UTT. Influences of Xeno-Free Media on Mesenchymal Stem Cell Expansion for Clinical Application. Tissue Eng Regen Med. 2021 Feb;18(1):15-23.
https://doi.org/10.1007/s13770-020-00306-z
PMid:33150562 PMCid:PMC7862486
38. Masuzawa Y, Kitazawa M. Synthetic polymers as xeno-free materials for stabilizing basic fibroblast growth factor in human mesenchymal stem cell cultures. Biochem Biophys Rep. 2021 Jan 29;25:100929.
https://doi.org/10.1016/j.bbrep.2021.100929
PMid:33553689 PMCid:PMC7848777
39. Bhat S, Viswanathan P, Chandanala S, Prasanna SJ, Seetharam RN. Expansion and characterization of bone marrow derived human mesenchymal stromal cells in serum-free conditions. Sci Rep. 2021 Feb 9;11(1):3403.
https://doi.org/10.1038/s41598-021-83088-1
PMid:33564114 PMCid:PMC7873235
40. Jonsdottir-Buch SM, Gunnarsdottir K, Sigurjonsson OE. Human Embryonic-Derived Mesenchymal Progenitor Cells (hES-MP Cells) are Fully Supported in Culture with Human Platelet Lysates. Bioengineering (Basel). 2020 Jul 20;7(3):75.
https://doi.org/10.3390/bioengineering7030075
PMid:32698321 PMCid:PMC7552691
41. Swain P., Nanda P.K., Nayak S.K., Mishra S.S. Basic techniques and limitations in establishing cell culture: A mini review. Adv. Anim. Vet. Sci. 2014. vol. 2. Р. 1-10.
https://doi.org/10.14737/journal.aavs/2014/2.4s.1.10
42. Mori T, Igarashi M, Onodera Y, Takehara T, Itokazu M, Teramura T. Fibrinogen supports self-renewal of mesenchymal stem cells under serum-reduced condition through autophagy activation. Biochem Biophys Res Commun. 2023 Apr 9;651:70-78.
https://doi.org/10.1016/j.bbrc.2023.02.009
PMid:36796212
43. Alona V. Zlatska, Roman G. Vasyliev, Inna M. Gordiienko, Anzhela E. Rodnichenko, Maria A. Morozova, Maria A. Vulf, Dmytro O. Zubov, Svitlana N. Novikova, Larisa S. Litvinova, Tatiana V. Grebennikova, Igor A. Zlatskiy, Anton V. Syroeshkin. Effect of the deuterium on efficiency and type of adipogenic differentiation of human adipose-derived stem cells in vitro. Sci Rep 10, 5217 (2020).
https://doi.org/10.1038/s41598-020-61983-3
PMid:32251307 PMCid:PMC7089999
44. Alona Zlatska, Inna Gordiienko, Roman Vasyliev, Dmitriy Zubov, Olga Gubar, Anzhela Rodnichenko, Anton Syroeshkin, and Igor Zlatskiy. In Vitro Study of Deuterium Effect on Biological Properties of Human Cultured Adipose-Derived Stem Cells – Scientific World Journal, Volume 2018, Article ID 5454367,
https://doi.org/10.1155/2018/5454367
PMid:30519147 PMCid:PMC6241234
45. Gubar OS, Rodnichenko AE, Vasyliev RG, Zlatska AV, Zubov DO. Postnatal extra-embryonic tissues as a source of multiple cell types for regenerative medicine applications. Exp Oncol. 2017 Sep;39(3):186-190.
https://doi.org/10.31768/2312-8852.2017.39(3):186-190
46. Zlatskiy IA, Zlatska AV, Antipova NV, Dolenko SA, Gordiienko IM, Gubar OS, Vasyliev RG, Zubov DA, Novikova SN, Syroeshkin AV. Comparative Analysis of the Different Dyes’ Potential to Assess Human Normal and Cancer Cell Viability In Vitro under Different D/H Ratios in a Culture Medium. ScientificWorldJournal. 2020 Feb 25;2020:2373021.
https://doi.org/10.1155/2020/2373021
PMid:32158363 PMCid:PMC7060866
47. R. I. Freshney, Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications, Wiley-Blackwell, 6th Ed edition, 2010.
https://doi.org/10.1002/9780470649367
48. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop Dj, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-7.
https://doi.org/10.1080/14653240600855905
PMid:16923606
49. Welsh JA, Goberdhan DCI, O’Driscoll L, Buzas EI, Blenkiron C, Bussolati B, Cai H, Di Vizio D, Driedonks TAP, Erdbrügger U, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024 Feb;13(2):e12404.
https://doi.org/10.1002/jev2.12451
PMid:38726651 PMCid:PMC11082720
50. Rädler J, Gupta D, Zickler A, Andaloussi SE. Exploiting the biogenesis of extracellular vesicles for bioengineering and therapeutic cargo loading. Mol Ther. 2023 May 3;31(5):1231-1250.
https://doi.org/10.1016/j.ymthe.2023.02.013
PMid:36805147 PMCid:PMC10188647

Gordiienko I, Shamshur M, Novikova S, Zlatskiy I, Zlatska A. Optimization of conditions for the production of small extracellular vesicles from human umbilical cord-derived mesenchymal stem cells. Cell Organ Transpl. 2025; 13(1):32-44 (e2025131175). doi: https://doi.org/10.22494/cot.v13i1.175

 

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.